July's Corporate Presentation is now on Cardiol's website, link is below.
In reviewing the 12 month milestones, there are only four listed right now.
Three have to do with current trials re: Covid, AM and Pre-Clincal Subcutaneous formulation.
The 4th is the NASDAQ listing, Elsley stated in the past he thought it occur 1st half of 2021 or very early Q3 2021, which we are in.
NASDAQ will be the next catalyst for the Share Price of the stock followed by the completion of the Covid trials.
On the latter Elsley stated the would announce when they hit the 1/2 way mark with patients, considering the first occurred in May, this seems to be a very slow roll out which is somewhat surprising given Covid is still a problem and there has been a lot of press about the impact of the vaccines on young patients regarding AM.
The share price is languishing right now, struggling to get to $3.0, it definitely needs a catalyst soon!
https://www.cardiolrx.com/wp-content/uploads/2021/07/Cardiol-Therapeutics-Corporate-Presentation-July-2021.pdf